Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2022-05-12 Director's Dealing
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities [CORRECTED]
Director's Dealing Classification · 99% confidence The document is an announcement regarding transactions in company securities by persons discharging managerial responsibilities (PDMRs). While it discusses insider dealings, the document itself is a short announcement (under 5,000 characters) that serves as a notification of these transactions and provides links to the actual detailed transaction reports (attachments). According to the 'Menu vs Meal' rule, this is an announcement of the filings rather than the filings themselves, and it specifically pertains to director/managerial dealings.
2022-05-12 English
Director's Dealing 2022
Director's Dealing Classification · 99% confidence The document is a formal template titled "Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them." It details a specific transaction (Vesting of Performance Share Units) by an executive (Christina S. Bredal, Vice President) of the issuer (Zealand Pharma A/S) on a specific date (May 12, 2022). This structure and content directly correspond to regulatory filings concerning insider transactions by management, which aligns precisely with the definition for Director's Dealing (DIRS).
2022-05-12 English
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for the notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMRs). It explicitly identifies the individual (Ivan M. Møller, an Executive Vice President), the issuer (Zealand Pharma A/S), and details the vesting of performance share units. This is a classic 'Director's Dealing' or 'PDMR Notification' filing.
2022-05-12 English
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It identifies the individual (Adam Steensberg, CEO), the issuer (Zealand Pharma A/S), and details a specific transaction involving the vesting of Performance Share Units. This is a classic Director's Dealing disclosure.
2022-05-12 English
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Report Publication Announcement Classification · 95% confidence The document is a company announcement regarding transactions in securities by persons discharging managerial responsibilities (PDMRs). While it mentions the transactions, it explicitly states 'Please see the attached files' and provides links to the actual notification documents. Following the 'Menu vs Meal' rule, since this is a short announcement directing the reader to the actual reports, it is classified as a Report Publication Announcement (RPA).
2022-05-12 English
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 99% confidence The document is titled "Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022" and explicitly states that Credit Suisse Group AG notified Zealand Pharma about a change in its total holding of shares and voting rights, referencing the Danish Capital Markets Act. This directly relates to changes in significant share ownership thresholds. The filing category 'Major Shareholding Notification' (MRQ) fits this description perfectly. Although it mentions an 'Attachment', the core content is the notification itself, not just an announcement of a report's publication (RPA/RNS).
2022-05-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.